🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT06965790
Recruiting Not applicable

Study on Sex-specific, Individualized Dose Calculation of Contrast Agent in CT Examinations

NCT06965790 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2025-04-01
Last updated
2025-12-09

Condition(s) studied

CT ScansContrast MediaGenderWomens Health

Investigational drug(s) / intervention(s)

contrast media (Imeron 350, active ingredient Iomeprol) volume according to sex-specific blood volume

contrast media (Imeron 350, active ingredient Iomeprol) volume according to sex-specific blood volume: Calculation of the standardized contrast agent (Imeron 350, active ingredient Iomeprol) quantity (0.35 g iodine/kg) and calculation of the specific blood volume using the established Nadler formula for male and female. Adjustment of the contrast agent according to the ratio of the blood volumes. The amount of saved contrast agent is replaced 1:1 by NaCl.

Study summary

A large proportion of radiological CT examinations require the intravenous administration of iodine-containing X-ray contrast medium. According to current guidelines, the amount required for CT examinations in the (portal) venous phase is calculated on the basis of body weight (e.g. 0.2-0.4 g iodine/kg body weight), but a standardized application dose of the contrast agent is often also used.

In earlier studies, the investigators found that the iodine contrast in vessels and organs achieved with a standardized amount of contrast agent differs significantly between women and men. On average, women showed around 10% higher iodine contrast than men of the same height and weight. The investigators attribute these differences to physiological, sex-specific differences in blood volume. For example, the blood volume of a woman 175 cm tall and weighing 75 kg is approx. 400 ml less than that of a man of the same height and weight (approx. 4.6 vs. 5.0 l, calculated according to Nadler). Taking blood volume into account, sex was no longer a significant influencing factor in a retrospective cohort (n=274).

The investigators would now like to investigate these results in a prospective study. For this purpose, two groups of patients with a clinical indication for a contrast-enhanced CT scan in the venous phase will be compared:

1. control group with regular weight-adjusted (n = 200)
2. study group with dosing according to blood volume (n = 200).

The hypothesis is that the application scheme adapted to the blood volume leads to a more homogeneous contrasting of women and men. In order to quantify this effect, the iodine contrast values of both groups will be quantitatively analyzed, taking into account other influencing variables (height, weight).

The investigators hope that this approach will reduce or even eliminate the observed sex-specific differences. This would lead to a sex-equal contrast based on an individualized amount of contrast medium.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Presence of a justifying indication for a CT scan of the thorax and abdomen with application of intravenous contrast medium and a start delay corresponding to the portal venous contrast medium phase * Ability to give informed consent, as well as written and verbal consent to participate in the study available Exclusion Criteria: * Cardiorespiratory instability (as assessed by the attending physician) * Age \<18 years * Existing or suspected pregnancy * Known post hepatectomy and/or splenectomy * Lack of current height (in the same inpatient/outpatient hospital stay) or lack of possibility of height measurement * Lack of current daily body weight or inability to measure body weight * Height under 140 cm or over 220 cm * Body weight under 50 kg or over 120 kg * Contraindication to iodine-containing contrast medium (Allergy to contrast media containing iodine, Severe renal insufficiency (eGFR \< 30 ml/min), Hyperthyroidism)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Hosptial Augsburg Augsburg Bavaria Recruiting

More University Hospital Augsburg trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06965790 on ClinicalTrials.gov ↗ ← All trials in Germany